SABS - SAB Biotherapeutics Inc

3.79
-0.020   -0.528%

Share volume: 155,952
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.17%

PREVIOUS CLOSE
CHG
CHG%
$3.81
-0.02
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
50%
Profitability 53%
Dept financing 25%
Liquidity 58%
Performance 51%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.56%
1 Month
-10.40%
3 Months
0.80%
6 Months
77.93%
1 Year
142.95%
2 Year
-30.97%
Key data
Stock price
$3.79
P/E Ratio 
1.12
DAY RANGE
$3.64 - $3.85
EPS 
-$0.85
52 WEEK RANGE
$1.00 - $6.60
52 WEEK CHANGE
$142.95
MARKET CAP 
20.926 M
YIELD 
N/A
SHARES OUTSTANDING 
47.607 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-19-2025
BETA 
-0.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$319,283
AVERAGE 30 VOLUME 
$296,914
Company detail
CEO: Eddie J. Sullivan
Region: US
Website: sabbiotherapeutics.com
Employees: 140
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Recent news